Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Subscribe To Our Newsletter & Stay Updated
